Frontiers in Microbiology (Oct 2022)
Gut microbiome and metabolites: The potential key roles in pulmonary fibrosis
- Yinlan Wu,
- Yinlan Wu,
- Yinlan Wu,
- Yanhong Li,
- Yanhong Li,
- Yanhong Li,
- Yubin Luo,
- Yubin Luo,
- Yubin Luo,
- Yu Zhou,
- Ji Wen,
- Ji Wen,
- Ji Wen,
- Lu Chen,
- Lu Chen,
- Lu Chen,
- Xiuping Liang,
- Xiuping Liang,
- Xiuping Liang,
- Tong Wu,
- Tong Wu,
- Tong Wu,
- Chunyu Tan,
- Chunyu Tan,
- Chunyu Tan,
- Yi Liu,
- Yi Liu,
- Yi Liu
Affiliations
- Yinlan Wu
- Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, China
- Yinlan Wu
- Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, China
- Yinlan Wu
- Institute of Immunology and Inflammation, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Chengdu, China
- Yanhong Li
- Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, China
- Yanhong Li
- Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, China
- Yanhong Li
- Institute of Immunology and Inflammation, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Chengdu, China
- Yubin Luo
- Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, China
- Yubin Luo
- Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, China
- Yubin Luo
- Institute of Immunology and Inflammation, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Chengdu, China
- Yu Zhou
- Department of Respiratory and Critical Care Medicine, Chengdu First People’s Hospital, Chengdu, China
- Ji Wen
- Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, China
- Ji Wen
- Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, China
- Ji Wen
- Institute of Immunology and Inflammation, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Chengdu, China
- Lu Chen
- Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, China
- Lu Chen
- Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, China
- Lu Chen
- Institute of Immunology and Inflammation, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Chengdu, China
- Xiuping Liang
- Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, China
- Xiuping Liang
- Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, China
- Xiuping Liang
- Institute of Immunology and Inflammation, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Chengdu, China
- Tong Wu
- Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, China
- Tong Wu
- Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, China
- Tong Wu
- Institute of Immunology and Inflammation, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Chengdu, China
- Chunyu Tan
- Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, China
- Chunyu Tan
- Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, China
- Chunyu Tan
- Institute of Immunology and Inflammation, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Chengdu, China
- Yi Liu
- Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, China
- Yi Liu
- Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, China
- Yi Liu
- Institute of Immunology and Inflammation, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Chengdu, China
- DOI
- https://doi.org/10.3389/fmicb.2022.943791
- Journal volume & issue
-
Vol. 13
Abstract
There are a wide variety of microbiomes in the human body, most of which exist in the gastrointestinal tract. Microbiomes and metabolites interact with the host to influence health. Rapid progress has been made in the study of its relationship with abenteric organs, especially lung diseases, and the concept the of “gut–lung axis” has emerged. In recent years, with the in-depth study of the “gut–lung axis,” it has been found that changes of the gut microbiome and metabolites are related to fibrotic interstitial lung disease. Understanding their effects on pulmonary fibrosis is expected to provide new possibilities for the prevention, diagnosis and even treatment of pulmonary fibrosis. In this review, we focused on fibrotic interstitial lung disease, summarized the changes the gut microbiome and several metabolites of the gut microbiome in different types of pulmonary fibrosis, and discussed their contributions to the occurrence and development of pulmonary fibrosis.
Keywords
